WSJ
24 Jul 2026, 07:24 UTC · 2h ago
Ipsen Drug Misses Goal in Late-Stage Trial for Rare Liver Disease
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
WSJ
24 Jul 2026, 07:24 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
1 claim · each scored for market impact
Bylvay failed to meet its primary study objective of improving native liver survival rates compared to a placebo. — Failure to meet a primary endpoint in a clinical trial significantly reduces the likelihood of regulatory approval and commercial viability for the drug.
-0.90Which stocks this story touches
The company's drug Bylvay failed to meet the primary objective of a clinical study regarding liver survival rates.
Continue reading
6 related stories
Search tags
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
WSJ
22h ago
